Compare Invesco Preferred ETF (PGX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs Stryker Corporation — how do they compare? Invesco Preferred ETF trades at $10.03 (market cap $3.60B), while Stryker Corporation trades at $276.9 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 29.5× Invesco Preferred ETF's market cap, and Stryker Corporation pays a 1.27% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Preferred ETF for 94 Days and Stryker Corporation for 20 Days on average.
| PGX | SYK | |
|---|---|---|
Market Cap | $3.60B | $106.24B |
Volume | 5,986,026 | 2,982,001 |
52-Week High | $11.61 | $388.35 |
52-Week Low | $9.97 | $269.75 |
Typical Hold Time | 94 Days | 20 Days |
Sector | — | Health |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $9.97, down 0.89% today, with technical indicators showing a bearish trend from moving averages but oversold signals from the RSI. The stock faces pressure amid mixed sentiment, with key support and resistance levels clustered around $10. Recent corporate actions include scheduled dividends for July and September 2026, but fundamental data such as P/E and profitability metrics are unavailable for analysis.
The outlook for PGX is cautious due to the bearish technical setup and lack of current fundamental visibility. Risks include potential volatility near the $10 level and dependence on future financial disclosures to assess valuation. Investment opportunity hinges on upcoming earnings reports clarifying growth and margins, while sentiment remains divided amid limited recent news coverage.
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
